European CHMP confirms recommendation to refuse marketing authorisation for sodium oxybate (Hopveus) for treatment of alcohol dependence

The Agency had concerns about several drawbacks in the design and analysis of the presented studies that could have affected the results. As the data were insufficient to establish its effectiveness, the Agency’s opinion was that the benefits did not outweigh its risks.


European Medicines Agency